Clinical Trial Update: TMC125-C223: TMC125 in HIV-1 Infected Subjects [Phase 2]

View source ↗

Summary

This document reports the completion of a Phase 2 study evaluating TMC125 (dapivirine) in HIV-1 infected subjects (TMC125-C223).

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• HIV Infection

Drugs mentioned

• TMC125 (dapivirine)

Snippet

Sponsor: Tibotec Pharmaceuticals, Ireland | Conditions: HIV Infection | Phase 2 | Status: COMPLETED